Abstract
The incidence of bronchiolitis obliterans syndrome (BOS), a devastating manifestation of chronic graft-versus-host-disease, may rise globally due to steady increases in utilization of allogeneic hematopoietic cell transplantation (HCT). Though some advances have occurred in the past decade regarding understanding of the pathogenesis, diagnosis and treatment of BOS, the overall mortality and morbidity remain very high. We sought to determine the current diagnostic and therapeutic challenges, which can potentially hinder optimal management of BOS both in developed and developing countries. We performed a comprehensive systematic review of both modern diagnostic modalities and treatments and then assessed which of them would be universally accessible. The 2014 National Institutes of Health chronic GVHD criteria remains the gold standard tool for diagnosing BOS. Important elements of treatment involve early and accurate detection, as well as utilizing the treatment modalities with known (but variable efficacy) e.g. fluticasone-azithromycin-montelukast [FAM] combination, etanercept, extra-corporeal photopheresis [ECP], lung transplantation, and prompt treatment of complications including infections in sufferers of BOS. Our results indicate that optimum diagnostic tools are not readily available in some parts of the world for early detection, which include a lack of CT scanners, unavailability of pulmonary function testing tools, absence of sub-specialists, lack of certain effective treatments and late referral for lung transplant. We present a systematic review of current literature along with recommendations for available therapies to guide practitioners to optimize the long-term outcomes in HCT survivors regardless of access to experts and expensive therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. New Engl J Med. 2014;370:1820–8.
Flowers ME, Apperley JF, Van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667–74.
Sakai R, Kanamori H, Nakaseko C, Yoshiba F, Fujimaki K, Sakura T, et al. Air-leak syndrome following allo-HCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant. 2011;46:379–84.
Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation—an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106–14.
Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129:448–55.
Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306–14.
Soubani A, Uberti J. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J. 2007;29:1007–19.
Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51:778–85.
Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24.
DUDEK AZ, MAHASETH H, DEFOR TE, WEISDORF DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657–66.
Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273–27.
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935–42.
Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after HCT. Bone Marrow Transplant. 2011;46:426–9.
Del Fante C, Galasso T, Bernasconi P, Scudeller L, Ripamonti F, Perotti C, et al. Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:728–32.
Child, FJ, Ratnavel, R, Watkins, P, Samson, D, Apperley, J, Ball, J, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant; 1999;23:881–7.
Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1044–54.
Lam DCL, Lam B, Wong MK, Lu C, Au WY, Tse EWC, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after HCT—a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011;46:1551–6.
Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25:490–3.
Norman BC, Jacobsohn DA, Williams KM, Au BKC, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic HCT: a case series of eight patients. Bone Marrow Transplant. 2011;46:1369–73.
Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:710–6.
Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant. 2005;36:135.
Ueda K, Watadani T, Maeda E, Ota S, Kataoka K, Seo S, et al. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic HCT. Bone Marrow Transplant. 2010;45:1719–27.
Holm AM, Riise GC, Hansson L, Brinch L, Bjørtuft Ø, Iversen M, et al. Lung transplantation for bronchiolitis obliterans syndrome after HCT. Bone Marrow Transplant. 2013;48:703–7.
Chen F, Yamane M, Inoue M, Shiraishi T, Oto T, Minami M, et al. Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. Am J Transplant. 2011;11:1509–16.
Gao, F, Chen, J, Wei, D, Wu, B and Zhou, M. Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation. Fron Med. 2017;12:224–8.
Cheng GS, Campbell AP, Xie H, et al. Correlation and agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2016;22:925–31.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.
Belloli EA, Degtiar I, Wang X, Yanik GA, Stuckey LJ, Verleden SE, et al. Parametric Response Mapping as an Imaging Biomarker in Lung Transplant Recipients. Am J Respir Crit Care Med. 2017;195:942–52.
Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, et al. Economic burden of epilepsy in India. Epilepsia. 2001;42:1052–60.
Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Santo Tomas LH, et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:337–44.
Cooke KR. A “window of opportunity” for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:291–2.
https://news.aamc.org/medical-education/article/new-aamc-research-reaffirms-looming-physician-shor/ Accessed 08 2017.
Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, et al. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009;15:1493–1501.
Schluger, Neil W, Charles Sherman. Notes from the field. Training pulmonary specialists in a low-income country. 2015;12:467–8.
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol/Oncol Stem Cell Ther. 2012;5:1–30.
Pronovost PJ. Enhancing physicians’ use of clinical guidelines. JAMA. 2013;310:2501–2.
Best care at lower cost: the path to continuously learning health care in America 2012. Institute of Medicine website, http://www.iom.edu /Reports/2012/Best-Care-at-Lower-Cost-The-Path-to-Continuously-Learning-Heaith-Care-in-America. Accessed 08 2017.
Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant. 2015;21:225–32.
Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1375–81.
Hashmi SK, Bredeson C, Duarte RF, Farnia S, Ferrey S, Fitzhugh C, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: the Healthcare Delivery Working Group report. Biol Blood Marrow Transplant. 2017;23:717–25.
GS Cheng, AP Campbell, H Xie, Z Correlation and agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients. BBMT 2016;22:925–31.
Link MP, Hagerty K, Kantarjian HM. Chemotherapy drug shortages in the United States: genesis and potential solutions. J Clin Oncol. 2012;30:692–4.
Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer—the example of mechlorethamine. New Engl J Med. 2012;367:2461–3.
Weill, D, Benden, C, Corris, PA, Dark, JH, Davis, RD, Keshavjee, S 2015. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.
Hook JL, Lederer DJ. Selecting lung transplant candidates: where do current guidelines fall short? Expert Rev Respir Med. 2012;6:51–61.
Greer M, Berastegui C, Jaksch P, Benden C, Aubert J, Roux A, et al. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience. Eur Respir J. 2018;51:1701330.
Gadre S, Turowski J, Budev M. Overview of lung transplantation, heart-lung transplantation, liver-lung transplantation, and combined hematopoietic stem cell transplantation and lung transplantation. Clin Chest Med. 2017;38:623–40.
Cheng GS, Edelman JD, Madtes DK, Martin PJ, Flowers ME. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1169–75.
Soubani AO, Kingah P, Alshabani K, Muma G, Haq A. Lung transplantation following hematopoietic stem cell transplantation: report of two cases and systematic review of literature. Clin Transplant. 2014;28:776–82.
Acknowledgements
Author contribution
AH and SKH wrote the first draft of the manuscript. All authors contributed substantially to the conception, acquisition, analysis, and interpretation of the data for the work and approved the final approval of the version to be published.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Hakim, A., Cooke, K.R., Pavletic, S.Z. et al. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplant 54, 383–392 (2019). https://doi.org/10.1038/s41409-018-0266-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0266-6
This article is cited by
-
Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Stem Cell Research & Therapy (2023)
-
A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
BMC Ophthalmology (2023)
-
Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation
Pediatric Research (2023)
-
Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2023)
-
Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2022)